252 related articles for article (PubMed ID: 26597111)
1. Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation.
Igarashi A; Goto R; Suwa K; Yoshikawa R; Ward AJ; Moller J
Appl Health Econ Health Policy; 2016 Feb; 14(1):77-87. PubMed ID: 26597111
[TBL] [Abstract][Full Text] [Related]
2. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
Getsios D; Marton JP; Revankar N; Ward AJ; Willke RJ; Rublee D; Ishak KJ; Xenakis JG
Pharmacoeconomics; 2013 Sep; 31(9):767-80. PubMed ID: 23821436
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
4. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
von Wartburg M; Raymond V; Paradis PE
Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment with varenicline is a cost-effective aid for smoking cessation.
Kautiainen K; Ekroos H; Puhakka M; Liira H; Laine J; Linden K; Hahl J
J Med Econ; 2017 Mar; 20(3):246-252. PubMed ID: 27754739
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
Tosanguan J; Chaiyakunapruk N
Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Hoogendoorn M; Welsing P; Rutten-van Mölken MP
Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany.
Aumann I; Treskova M; Hagemann N; von der Schulenburg JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):441-452. PubMed ID: 27021824
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
12. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
O'Donnell MP; Roizen MF
Am J Health Promot; 2011; 26(1):e11-23. PubMed ID: 21879928
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010-2011 Tobacco Use Supplement to the Current Population Survey.
Smith PH; Zhang J; Weinberger AH; Mazure CM; McKee SA
Drug Alcohol Depend; 2017 Sep; 178():485-491. PubMed ID: 28715776
[TBL] [Abstract][Full Text] [Related]
14. An examination of user costs in relation to smokers using a cessation service based in the UK.
Walker N; Yang Y; Kiparoglou V; Pokhrel S; Robinson H; van Woerden H
BMC Health Serv Res; 2018 Mar; 18(1):182. PubMed ID: 29544477
[TBL] [Abstract][Full Text] [Related]
15. Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework.
Connolly MP; Baker CL; Kotsopoulos N
J Med Econ; 2018 Jun; 21(6):571-576. PubMed ID: 29376747
[TBL] [Abstract][Full Text] [Related]
16. [Cost-Effectiveness of Pharmacological Smoking Cessation Therapies - A Systematic Literature Review].
Aumann I; Rozanski K; Damm K; Graf von der Schulenburg JM
Gesundheitswesen; 2016 Oct; 78(10):660-671. PubMed ID: 27784123
[No Abstract] [Full Text] [Related]
17. French smoking cessation services provide effective support even to the more dependent.
Baha M; Boussadi A; Le Faou AL
Prev Med; 2016 Sep; 90():34-8. PubMed ID: 27346755
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.
Igarashi A; Takuma H; Fukuda T; Tsutani K
Pharmacoeconomics; 2009; 27(3):247-61. PubMed ID: 19354344
[TBL] [Abstract][Full Text] [Related]
19. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
20. Motivational Interviewing to Encourage Quit Attempts Among Smokers Not Ready to Quit: A Trial-Based Economic Analysis.
Rasu RS; Thelen J; Agbor Bawa W; Goggin K; Bradley-Ewing A; Catley D
Nicotine Tob Res; 2020 Aug; 22(9):1515-1523. PubMed ID: 31820002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
